VIVOS 2025 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance:

Vivos Therapeutics, Inc. reported a 6% decline in Q2 2025 revenue to $3.8 million compared to $4.1 million in Q2 2024, primarily driven by a $1 million drop in VIP enrollment revenue as the company pivots away from its legacy model. For the first half of 2025, revenue decreased by 9% to $6.8 million. However, the acquisition of Sleep Center of Nevada (SCN) offset some of the decline, contributing $500,000 in sleep testing revenue since mid-June. Appliance sales decreased by 5% year-over-year, but guide sales partially offset the decline. Operating expenses rose due to acquisition costs, widening the quarterly operating loss to $4.9 million. The company secured $11.5 million in financing to support its strategic transition.

Company Outlook & Strategy:

Vivos is transitioning to a sleep center provider-based alliance and acquisition model, with SCN serving as a cornerstone for growth. The company plans to deploy additional Sleep Optimization (SO) teams to meet increasing patient demand, expand SCN's physical facilities, and integrate similar acquisitions in new markets. By 2026, Vivos anticipates deploying up to eight SO teams at SCN, each capable of processing 250 patients monthly and generating $500,000 in revenue per team. The company is also rolling out a pediatric OSA program and refining its collaboration model for non-acquisition partnerships with sleep centers.

Key Industry Trends:

Vivos flagged strong demand for alternatives to CPAP therapy among OSA patients, reflecting broader industry interest in innovative sleep disorder solutions. Additionally, the rise in collaborative models between sleep centers and specialized providers highlights growing integration across the healthcare space. Credentialing processes with third-party payers remain a bottleneck for scaling operations.

Operational Highlights:

• SCN Acquisition: Since acquiring SCN, Vivos has seen higher-than-anticipated patient demand, prompting facility expansions and the rapid deployment of SO teams.
• SO Teams: One and a half SO teams are operational at SCN, with plans to increase to four and a half teams by 2026. These teams emphasize patient education and treatment optimization, driving higher patient throughput.
• Expansion Plans: SCN locations are being expanded to accommodate additional teams. A similar collaboration model was initiated in Michigan with MI Sleep, LLC, with operations expected to begin in Q4 2025.
• Revenue Diversification: Sleep testing services and sponsorships contributed significantly to Q2 revenue growth.

Challenges & Risks:

• Revenue Decline: The pivot away from the legacy VIP enrollment model has led to short-term revenue declines, which may continue until the new model scales fully.
• High Operating Expenses: Acquisition and integration costs, including professional fees and infrastructure expenses, have widened operating losses.
• Scaling Challenges: Credentialing processes with payers may delay the onboarding of new providers and limit immediate scalability.
• Execution Risk: The success of the new model relies heavily on deploying SO teams efficiently and sustaining patient demand.

Key Analyst Questions & Responses:

1. Revenue Growth: Analysts inquired about Q3 and Q4 revenue expectations. Management indicated revenue growth will track the deployment of SO teams, with higher-margin revenues from the new model replacing legacy revenue streams.
2. Sleep Testing Services: Analysts asked if sleep testing and sponsorship revenues would continue to grow. Management confirmed that SCN operations are driving testing revenue growth and are expected to expand further as new testing centers are integrated.
3. Sequential Revenue Increase: The company highlighted a 27% sequential revenue growth from Q1 to Q2 due to contributions from SCN and growth in product referrals.

This summary captures the key insights from the earnings call, providing a concise overview of the company's financial performance, strategic initiatives, industry trends, operational updates, and risks, along with highlights from the Q&A session.